Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts

Charles River Laboratories advanced during the quarter after a strong earnings report and an increase to full-year guidance. The portfolio exited Norwegian Cruise Line Holdings and redeployed the proceeds into Royal Caribbean Group. Middleby completed the spin-off of Midera Food Processing, said it plans to exit an underperforming business, and continued share repurchases.

Analysis

The most actionable signal is CRL’s guidance trajectory, not the quarter’s share-price response. If higher guidance is supported by organic demand, bookings and utilization, stronger lab volumes could improve operating leverage and support estimates; a single quarter does not establish a durable recovery in biotech-funded demand, which can affect CRO work with a lag. Watch subsequent bookings/backlog commentary and biotech financing conditions. A reversal in guidance or weaker demand indicators would undermine the thesis.

For MIDD, restructuring may reduce the conglomerate discount only if the remaining business shows cleaner organic growth and cash conversion. The spin-off and buybacks alone do not prove value creation: stranded costs, separation expenses and repurchase funding could offset the benefit. Verify post-separation segment disclosures and free cash flow before assigning credit.

RCL’s relative appeal versus NCLH depends on operating evidence—particularly pricing, bookings and balance-sheet progress—not the portfolio rotation itself. Near term, the market can reward cruise demand; over 1–3 months, fuel, labor and consumer-spending signals matter. Over 6–18 months, capacity and debt servicing can constrain returns even if demand holds. Without comparative valuation and operating data, the rotation is not enough to justify a standalone pair trade.

Key Decisions for Investors

• CRL: Do not chase the initial reaction. Consider initiating or adding only if the next report sustains guidance through organic growth and bookings/utilization; reassess on a guidance cut or deterioration in demand commentary. Compare estimate revisions with IQVIA and Medpace rather than assuming CRL’s result lifts the whole CRO group.
• MIDD: Keep neutral pending post-spin reporting. Track standalone organic sales, free cash flow, separation/stranded costs and repurchase funding; treat buybacks as supportive only if cash generation remains intact.
• RCL/NCLH: Avoid treating the exit-and-redeployment as evidence of a durable relative edge. Revisit a RCL-over-NCLH position only after comparing pricing/bookings, debt metrics and valuation; weaker RCL pricing or adverse fuel and consumer-spending trends would falsify the case.
• Near-term catalyst watch: CRL’s next guidance and demand update; MIDD’s first clean post-separation financial disclosures; and cruise-company updates on bookings, pricing and balance-sheet progress.